Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry.

Abstract:

PURPOSE:To examine the California Cancer Registry (CCR) for bladder cancer survival disparities based on race, socioeconomic status (SES), and insurance in California patients. PATIENTS AND METHODS:The CCR was queried for bladder cancer cases in California from 1988 to 2012. The primary outcome was disease-specific survival (DSS), defined as the time interval from date of diagnosis to date of death from bladder cancer. Survival analyses were performed to determine the prognostic significance of racial and socioeconomic factors. RESULTS:A total of 72,452 cases were included (74.5% men, 25.5% women). The median age was 72 years (range, 18-109 years). The racial distribution among the patients was 81% white, 3.8% black, 8.8% Hispanic, 5.2% Asian, and 1.2% from other races. In black patients, tumors presented more frequently with advanced stage and high grade. Medicaid patients tended to be younger and had more advanced-stage, higher-grade tumors compared to patients with Medicare or managed care (P < .0001). Kaplan-Meier analysis demonstrated significantly poorer 5-year DSS in black, low SES, and Medicaid patients (P < .0001). When controlling for stage, grade, age, and gender, multivariate analysis revealed that black race (DSS hazard ratio = 1.295; 95% confidence interval, 1.212-1.384), low SES (DSS hazard ratio = 1.325; 95% confidence interval, 1.259-1.395), and Medicaid insurance (DSS hazard ratio = 1.349; 95% confidence interval, 1.246-1.460) were independent prognostic factors (P < .0001). CONCLUSION:An analysis of the CCR demonstrated that black race, low SES, and Medicaid insurance portend poorer DSS. These findings reflect a multifaceted socioeconomic and public health conundrum, and efforts to reduce inequalities should be pursued.

journal_name

Clin Genitourin Cancer

authors

Sung JM,Martin JW,Jefferson FA,Sidhom DA,Piranviseh K,Huang M,Nguyen N,Chang J,Ziogas A,Anton-Culver H,Youssef RF

doi

10.1016/j.clgc.2019.05.008

subject

Has Abstract

pub_date

2019-10-01 00:00:00

pages

e995-e1002

issue

5

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(19)30146-6

journal_volume

17

pub_type

杂志文章
  • Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer.

    abstract:BACKGROUND:The objective of this study was to investigate whether the prior use of a novel androgen receptor-axis-targeted (ARAT) agent with or without subsequent taxane therapy could affect the efficacy of another ARAT agent in patients with metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHOD...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.07.005

    authors: Miyake H,Hara T,Ozono S,Fujisawa M

    更新日期:2017-04-01 00:00:00

  • Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer.

    abstract:BACKGROUND:We investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT) efficacy. PATIENTS AND METHODS:Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using r...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.03.006

    authors: Kohli M,Oberg AL,Mahoney DW,Riska SM,Sherwood R,Zhang Y,Zenka RM,Sahasrabudhe D,Qin R,Zhang S

    更新日期:2019-08-01 00:00:00

  • Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer.

    abstract:BACKGROUND:The objective of this study was to investigate positive surgical margin (PSM) rates in patients with prostate cancer treated with radical prostatectomy (RP) and assess PSM impact on cancer-specific mortality (CSM). PATIENTS AND METHODS:Within the Surveillance, Epidemiology, and End Results (SEER) database (...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.09.024

    authors: Preisser F,Mazzone E,Knipper S,Nazzani S,Bandini M,Shariat SF,Tian Z,Saad F,Montorsi F,Zorn KC,Graefen M,Tilki D,Karakiewicz PI

    更新日期:2019-02-01 00:00:00

  • Laparoscopic Partial Nephrectomy After Selective Embolization and Robot-Assisted Partial Nephrectomy: A Comparison of Short-Term Oncological and Functional Outcomes.

    abstract:BACKGROUND:Partial nephrectomy (PN) is the standard treatment for localized renal tumors. Laparoscopic PN (LPN) after selective embolization of tumor (LPNE) in a hybrid operating room has been developed to make LPN easier and safer. The aim of this study was to compare outcomes of LPNE and robot-assisted PN (RAPN). PA...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.07.005

    authors: Benoit M,Bouvier A,Panayotopoulos P,Culty T,Guillonneau B,Aube C,Azzouzi AR,Sebe P,Bigot P

    更新日期:2018-12-01 00:00:00

  • Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.

    abstract:INTRODUCTION:Clinical T1 (cT1) bladder cancer is associated with high rates of recurrence, upstaging, and progression. Guidelines recommend that these patients be treated with adjuvant intravesical Bacillus Calmette-Guérin immunotherapy (BCG) or upfront radical cystectomy (RC). We analyzed the National Cancer Database ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.01.007

    authors: Balakrishnan AS,Washington SL 3rd,Meng MV,Porten SP

    更新日期:2019-06-01 00:00:00

  • Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.

    abstract:BACKGROUND:Carcinoma of the collecting ducts (CDC) of Bellini of the kidney is very rare but is among the most aggressive urologic entities. PATIENTS AND METHODS:Radical nephrectomy revealed CDC in stage pT3a pN2 M0 G3 in 2 male patients. Four courses of adjuvant chemotherapy with cisplatin and gemcitabine were given....

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2009.n.010

    authors: Staehler M,Schöppler G,Haseke N,Stadler T,Karl A,Siebels M,Ihrler S,Stief CG

    更新日期:2009-01-01 00:00:00

  • Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.

    abstract:INTRODUCTION:In the first-line (1L) setting, pazopanib (PAZ) has been recommended by the National Comprehensive Cancer Network for the treatment of advanced renal cell carcinoma (aRCC). In 2018, immuno-oncology (IO) therapy became a commonly used 1L treatment option for aRCC. We report the real-world clinical outcomes ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2019.10.010

    authors: Cao X,Tang D,Ratto B,Poole A,Ravichandran S,Jin L,Gao W,Swallow E,Vogelzang NJ

    更新日期:2020-02-01 00:00:00

  • The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs).

    abstract:BACKGROUND:Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are linked to prostate cancer, but their effect on biochemical recurrence (BR) remains unknown. Our aims were to investigate the incidence and risk of BR in men on ACEIs/ARBs after radical radiotherapy with adjuvant∖neo...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.03.009

    authors: Alashkham A,Paterson C,Windsor P,Struthers A,Rauchhaus P,Nabi G

    更新日期:2016-10-01 00:00:00

  • Gynecologic Organ Involvement During Radical Cystectomy for Bladder Cancer: Is It Time to Routinely Spare the Ovaries?

    abstract:PURPOSE:To determine a subset of women who could undergo ovary-sparing radical cystectomy (OSRC) for bladder cancer without compromising oncologic safety. PATIENTS AND METHODS:A retrospective review was performed of 164 consecutive women who underwent cystectomy at a single tertiary-care center from 1997 to 2018. Clin...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.10.009

    authors: Taylor BL,Matrai CE,Smith AL,Ayangbesan A,Xia L,Golombos DM,Mosquera JM,Nicolas J,Robinson BD,Scherr DS,Khani F

    更新日期:2019-02-01 00:00:00

  • A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis.

    abstract:BACKGROUND:Consistent with other data sets, our own institutional series suggests that survival in patients aged ≥ 75 years with metastatic renal cell carcinoma (mRCC) is inferior to that in patients < 75 years. We sought to confirm these trends through exploration of the Surveillance, Epidemiology and End Results (SEE...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2013.04.011

    authors: Nelson RA,Vogelzang N,Pal SK

    更新日期:2013-09-01 00:00:00

  • Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.

    abstract:BACKGROUND:Frontline treatment of metastatic castration-resistant prostate cancer (mCRPC) consists of docetaxel-based chemotherapy. The median time to progression (TTP) from chemotherapy initiation is 6 to 8 months. Ketoconazole, a nonspecific cytochrome P17 inhibitor (CYP17i), blocks adrenal androgen synthesis. Low-do...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2012.11.003

    authors: Gil-Bazo I,Arévalo E,Castillo A,Zudaire ME,Carranza OE,Fusco JP,Castañón E,Collado-Gómez V,López I,Gil-Aldea I

    更新日期:2013-06-01 00:00:00

  • Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.

    abstract:PURPOSE:To determine the therapeutic value of lymph node dissection (LND) during cytoreductive nephrectomy (CN) and assess predictors of cancer-specific survival (CSS) in metastatic renal-cell carcinoma. PATIENTS AND METHODS:We identified 293 consecutive patients treated with CN at 4 academic institutions from March 2...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2017.10.004

    authors: Chipollini J,Abel EJ,Peyton CC,Boulware DC,Karam JA,Margulis V,Master VA,Zargar-Shoshtari K,Matin SF,Sexton WJ,Raman JD,Wood CG,Spiess PE

    更新日期:2018-04-01 00:00:00

  • Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma.

    abstract:INTRODUCTION:The introduction of active new agents, such as small molecules and checkpoint inhibitors, for the treatment of metastatic renal-cell cancer (mRCC) is associated with a relevant increase in costs, and it is therefore important to strike a balance between the costs of treatment and the added value represente...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.02.006

    authors: Giuliani J,Bonetti A

    更新日期:2018-06-01 00:00:00

  • Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer.

    abstract:OBJECTIVES:The aim of this study was to evaluate the expression of MIB-1, BCL-2, VEGFR3, and CD31 and their associations with long-term survival in patients with renal cell cancer (RCC). PATIENTS AND METHODS:This study consisted of 224 RCC patients who underwent radical nephrectomy from 1985 to 1995. Follow-up continu...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.12.014

    authors: Virman JP,Bono P,Luukkaala TH,Sunela KL,Kujala PM,Kellokumpu-Lehtinen PL

    更新日期:2016-08-01 00:00:00

  • Expression of microRNAs in the urine of patients with bladder cancer.

    abstract:UNLABELLED:We quantified the urine sediment and supernatant levels of microRNA (miRNA) targets related to epithelial-mesenchymal transition in 51 patients with bladder cancer and in 24 controls. We found that patients with bladder cancer had depressed levels of the miR-200 family, miR-192, and miR-155 in urinary sedime...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2012.01.001

    authors: Wang G,Chan ES,Kwan BC,Li PK,Yip SK,Szeto CC,Ng CF

    更新日期:2012-06-01 00:00:00

  • Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy.

    abstract:BACKGROUND:Neutrophil-to-lymphocyte ratio (NLR) might reflect an increased neutrophilic inflammatory response, and urothelial tumors with squamous-cell features (SqD) have been linked to inflammation. We hypothesized that NLR could be prognostic in these patients. PATIENTS AND METHODS:In patients with SqD muscle-invas...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.01.024

    authors: Buisan O,Orsola A,Oliveira M,Martinez R,Etxaniz O,Areal J,Ibarz L

    更新日期:2017-08-01 00:00:00

  • What Have Patients Been Hearing From Providers Since the 2012 USPSTF Recommendation Against Routine Prostate Cancer Screening?

    abstract:BACKGROUND:In this study we aimed to determine the relationship between prostate-specific antigen (PSA)-related information obtained from the provider and PSA test uptake. With recent focus on patient-provider communication (PC) and the guidelines recommending against PSA tests for prostate cancer (PCa), PC regarding t...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.05.002

    authors: Haider MR,Qureshi ZP,Horner R,Friedman DB,Bennett C

    更新日期:2017-12-01 00:00:00

  • Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.

    abstract:BACKGROUND:Cisplatin-based neoadjuvant chemotherapy (NAC) before cystectomy improves survival in muscle-invasive urothelial bladder cancer (MIBC). The use of NAC before chemoradiation (CRT) has been limited, as these patients are often elderly, frail, and ineligible for cisplatin. However, the role of NAC in fit, cispl...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.09.021

    authors: Jiang DM,Jiang H,Chung PWM,Zlotta AR,Fleshner NE,Bristow RG,Berlin A,Kulkarni GS,Alimohamed NS,Lo G,Sridhar SS

    更新日期:2019-02-01 00:00:00

  • Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.

    abstract:BACKGROUND:The purpose of this study was to compare the efficacy of 2 bacillus Calmette-Guérin (BCG) strains, BCG-Tice and BCG-Moreau, in the treatment of non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS:We retrospectively reviewed clinical data from patients treated with BCG for NMIBC at 3 academic c...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2019.10.021

    authors: D'Andrea D,Soria F,Abufaraj M,Pones M,Gontero P,Machado AT,Waksman R,Enikeev DV,Glybochko PV,Adonias SP,Nahas WC,Shariat SF,Chade DC

    更新日期:2020-02-01 00:00:00

  • Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors.

    abstract:BACKGROUND:We comprehensively tested contemporary incidence and mortality rates in patients with germ cell tumor of the testis (GCTT). MATERIALS AND METHODS:Within the Surveillance, Epidemiology, and End Results database (2004-2015), statistical analyses included estimated annual percentage changes, multivariable logi...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.06.003

    authors: Palumbo C,Mistretta FA,Mazzone E,Knipper S,Tian Z,Perrotte P,Antonelli A,Montorsi F,Shariat SF,Saad F,Simeone C,Briganti A,Lattouf JB,Karakiewicz PI

    更新日期:2019-10-01 00:00:00

  • Clinical Significance of Subclassification of Papillary Renal Cell Carcinoma: Comparison of Clinicopathologic Parameters and Oncologic Outcomes Between Papillary Histologic Subtypes 1 and 2 Using the Korean Renal Cell Carcinoma Database.

    abstract:INTRODUCTION:The aims of the present study were to compare the clinicopathologic characteristics between type 1 and type 2 papillary renal cell carcinoma (pRCC) and to evaluate the effect of the subclassification of pRCC on the oncologic outcomes after surgery. MATERIALS AND METHODS:The records of 274 patients with pR...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.07.020

    authors: Ha YS,Chung JW,Choi SH,Lee JN,Kim HT,Kim TH,Chung SK,Byun SS,Hwang EC,Kang SH,Hong SH,Chung J,Kwak C,Kim YJ,Kwon TG,Korean Renal Cell Carcinoma Study Group.

    更新日期:2017-04-01 00:00:00

  • Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study.

    abstract:BACKGROUND:The present study tested cancer-specific (CSM) and overall mortality (OM) after partial cystectomy (PC) for variant histology bladder cancer (non-urothelial carcinoma of the urinary bladder UCUB), relative to UCUB and relative to radical cystectomy (RC). MATERIALS AND METHODS:Within the Surveillance, Epidem...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.10.016

    authors: Luzzago S,Palumbo C,Rosiello G,Knipper S,Pecoraro A,Deuker M,Mistretta FA,Tian Z,Musi G,Montanari E,Shariat SF,Saad F,Briganti A,de Cobelli O,Karakiewicz PI

    更新日期:2020-04-01 00:00:00

  • Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer.

    abstract:BACKGROUND:The most common presenting symptom of bladder cancer (BCa) is hematuria. The present study was designed to define whether patients taking antiplatelet and/or anticoagulant drugs might experience hematuria at an earlier stage or grade of BCa. PATIENTS AND METHODS:The data from 1532 consecutive patients who p...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.08.003

    authors: Moschini M,Karnes RJ,Suardi N,Bianchi M,Pellucchi F,Rocchini L,Damiano R,Serretta V,Salonia A,Montorsi F,Briganti A,Colombo R

    更新日期:2016-06-01 00:00:00

  • Metabolic syndrome as a peculiar target for management of prostate cancer patients.

    abstract::An interesting and reciprocal association between the metabolic syndrome and prostate cancer has been identified. Metabolic alterations, such as hyperinsulinemia, increased levels of insulin growth factor-1, and insulin resistance could be on the basis of development and progression of many tumors, including prostate ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2013.04.009

    authors: Conteduca V,Di Lorenzo G,Bozza G,Ardito R,Aieta M

    更新日期:2013-09-01 00:00:00

  • Unravelling Adrenal Oncocytic Neoplasm.

    abstract::Oncocytic neoplasms are rare tumors arising in the adrenal glands and usually considered as nonfunctional and benign. We report 4 cases of adrenal oncocytic neoplasm. The paucity of literature describing this entity increases the chance for misdiagnosis. Confirmatory diagnosis is by tissue sampling with adrenalectomy ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2018.10.011

    authors: Virarkar M,Patnana M,Vikram R,Bhargava P,Birkenfeld E,Sagebiel T

    更新日期:2019-02-01 00:00:00

  • Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.

    abstract:BACKGROUND:A rapid progression pattern called hyperprogressive disease (HPD) has been observed during early cycles of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor therapy. Data regarding HPD in patients with genitourinary cancer are limited. PATIENTS AND METHODS:We included 203 pa...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.09.009

    authors: Hwang I,Park I,Yoon SK,Lee JL

    更新日期:2020-04-01 00:00:00

  • Partial nephrectomy for the treatment of translocation renal cell carcinoma.

    abstract:BACKGROUND:The aim of this study was to evaluate the outcome of patients with translocation renal cell carcinoma (RCC) treated with partial nephrectomy. PATIENTS AND METHODS:Our institutional review board-approved renal mass registry was queried for patients who underwent partial nephrectomy for a pathologically confi...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.12.008

    authors: Gorin MA,Ball MW,Pierorazio PM,Argani P,Allaf ME

    更新日期:2015-06-01 00:00:00

  • Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.

    abstract:BACKGROUND:Scatter factor, also known as hepatocyte growth factor (SF/HGF), is a polypeptide growth factor thought to be important in the growth and spread of prostatic carcinoma. PATIENTS AND METHODS:Scatter factor/HGF levels in pretreatment plasma samples from 171 men with metastatic hormone-refractory prostate canc...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2006.n.006

    authors: Humphrey PA,Halabi S,Picus J,Sanford B,Vogelzang NJ,Small EJ,Kantoff PW

    更新日期:2006-03-01 00:00:00

  • Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.

    abstract:BACKGROUND:Sunitinib malate, a targeted tyrosine kinase inhibitor, is standard of care for metastatic renal cell carcinoma (mRCC) and serves as the active comparator in several ongoing mRCC clinical trials. In this analysis we report benchmarks for clinical outcomes on the basis of International Metastatic Renal Cell C...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clgc.2018.04.005

    authors: Rini BI,Hutson TE,Figlin RA,Lechuga MJ,Valota O,Serfass L,Rosbrook B,Motzer RJ

    更新日期:2018-08-01 00:00:00

  • Development of a Novel Prognostic Risk Score for Predicting Complications of Penectomy in the Surgical Management of Penile Cancer.

    abstract:INTRODUCTION:Penectomy for PC is useful in staging, disease prognosis, and treatment. Limited studies have evaluated its surgical complications. We sought to assess these complications and determine predictive models to create a novel risk score for penectomy complications. PATIENTS AND METHODS:A retrospective review ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.09.018

    authors: Velazquez N,Press B,Renson A,Wysock JS,Taneja S,Huang WC,Bjurlin MA

    更新日期:2019-02-01 00:00:00